InVivoPlus anti-mouse PD-1 (CD279)

RRID:AB_1107747
Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0033-2, RRID:AB_1107747)

Antibody Information

URL: http://antibodyregistry.org/AB_1107747

Proper Citation: (Bio X Cell Cat# BE0033-2, RRID:AB_1107747)

Target Antigen: PD-1 (CD279)

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization Consolidation on 12/2021: AB_1107747, AB_2894791.

Antibody Name: InVivoPlus anti-mouse PD-1 (CD279)

Description: This monoclonal targets PD-1 (CD279)

Target Organism: mouse

Clone ID: clone J43

Antibody ID: AB_1107747

Vendor: Bio X Cell

Catalog Number: BE0033-2

Alternative Catalog Numbers: BE0033-2-1MG, BP0033-2-100MG, BP0033-2-50MG, BE0033-2-25MG, BP0033-2-5MG, BE0033-2-5MG, BE0033-2-50MG, BE0033-2-100MG, BP0033-2-25MG

Record Creation Time: 20231110T031700+0000

Record Last Update: 20240725T092623+0000

Ratings and Alerts

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Wu S, et al. (2023) Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment. Cancer research communications, 3(8), 1460.

Rossignol J, et al. (2022) Neuropilin-1 cooperates with PD-1 in CD8+ T cells predicting outcomes in melanoma patients treated with anti-PD1. iScience, 25(6), 104353.

Brinch SA, et al. (2022) The Tankyrase Inhibitor OM-153 Demonstrates Antitumor Efficacy and a Therapeutic Window in Mouse Models. Cancer research communications, 2(4), 233.

Meng J, et al. (2022) Tumor-derived Jagged1 promotes cancer progression through immune evasion. Cell reports, 38(10), 110492.

Teijeira A, et al. (2022) Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy. Cancer research, 82(23), 4373.

Sharma MD, et al. (2021) Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity. Immunity, 54(10), 2354.

Kato D, et al. (2020) GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab. eLife, 9.

Rudd CE, et al. (2020) Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity. Cell reports, 30(7), 2075.

Hu Z, et al. (2019) Acylglycerol Kinase Maintains Metabolic State and Immune Responses of CD8+ T Cells. Cell metabolism, 30(2), 290.

Sharma MD, et al. (2018) Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors. Immunity, 48(1), 91.

Li J, et al. (2018) Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8+ T Cells. Immunity, 48(4), 773.

Xia Y, et al. (2018) The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery. Cell, 175(4), 1059.